Track Conexeu Sciences Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Conexeu Sciences Inc. CNXU · Stock Open Conexeu Sciences Inc. in new tab

16.00 USD
EPS
-0.26
P/B
41.69
Loading chart...
Key Metrics
Earnings dateSept. 30, 2026
EPS-0.26
Book Value0.34
Price to Book41.69
Debt/Equity0.06
% Insiders43.416%

DCF Valuation

Tweak assumptions to recompute fair value for Conexeu Sciences Inc. (CNXU)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Conexeu Sciences Inc. Logo Conexeu Sciences Inc. Analysis (CNXU)

US Healthcare Official Website Stock

Is Conexeu Sciences Inc. a good investment? Conexeu Sciences Inc. (CNXU) is currently trading at 16.00 USD.

Earnings Schedule: Conexeu Sciences Inc. is expected to release its next earnings report on Sept. 30, 2026.

Investor FAQ

Does Conexeu Sciences Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Conexeu Sciences Inc.?

Conexeu Sciences Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Sept. 30, 2026. The company currently has a trailing EPS of -0.26.

Company Profile

Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.

Exchange Ticker
NASDAQ CNXU
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion